← Back to Screener
Ernexa Therapeutics Inc. Common Stock (ERNA)
Price$9.12
Value ScoreC
Growth ScoreF
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-82.90%
Price vs S&P 500 (4W)172.46%
VGM Score27.68
Market Capitalization$11.62M
All Metrics
Book Value / Share (Quarterly)$5.88
P/TBV (Annual)0.78x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-69.14%
Cash Flow / Share (Quarterly)$-6.22
Price vs S&P 500 (YTD)-75.70%
Gross Margin (TTM)83.51%
Net Profit Margin (TTM)-7720.96%
EPS (TTM)$-25.77
10-Day Avg Trading Volume0.23M
EPS Excl Extra (TTM)$-25.77
Revenue Growth (5Y)-51.31%
EPS (Annual)$-55.83
Dividend / Share (Annual)$0.00
ROI (Annual)-446.97%
Gross Margin (Annual)83.51%
Net Profit Margin (5Y Avg)-7921.03%
Cash / Share (Quarterly)$7.87
ROA (Last FY)-241.41%
Revenue Growth TTM (YoY)-99.83%
EBITD / Share (TTM)$-7.67
ROE (5Y Avg)-971.78%
Operating Margin (TTM)-6600.34%
Cash Flow / Share (Annual)$-22.45
P/B Ratio1.69x
P/B Ratio (Quarterly)0.85x
Net Income / Employee (Annual)$-2,816,800
EV / Revenue (TTM)4.62x
Net Interest Coverage (TTM)-5.41x
ROA (TTM)-228.54%
EPS Incl Extra (Annual)$-55.83
Current Ratio (Annual)1.01x
Quick Ratio (Quarterly)2.68x
3-Month Avg Trading Volume1.17M
52-Week Price Return-87.74%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.36
P/S Ratio (Annual)19.96x
Asset Turnover (Annual)0.11x
52-Week High$90.00
Operating Margin (5Y Avg)-7549.30%
EPS Excl Extra (Annual)$-55.83
CapEx CAGR (5Y)-32.80%
Tangible BV CAGR (5Y)26.77%
26-Week Price Return-66.97%
Quick Ratio (Annual)0.88x
13-Week Price Return40.93%
Total Debt / Equity (Annual)0.31x
Current Ratio (Quarterly)2.89x
Enterprise Value$2.69M
Revenue / Share Growth (5Y)-71.73%
Asset Turnover (TTM)0.02x
Book Value / Share Growth (5Y)-51.48%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)21.45x
Pretax Margin (Annual)-7647.59%
Cash / Share (Annual)$6.00
3-Month Return Std Dev218.12%
Gross Margin (5Y Avg)2.78%
Net Income / Employee (TTM)$-2,816,600
ROE (Last FY)-586.59%
Net Interest Coverage (Annual)-5.47x
EPS Basic Excl Extra (Annual)$-55.83
P/FCF (TTM)7.04x
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.04x
EPS Incl Extra (TTM)$-25.77
Receivables Turnover (Annual)0.00x
ROI (TTM)-158.02%
P/S Ratio (TTM)19.96x
Pretax Margin (5Y Avg)-7920.90%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.36
Price vs S&P 500 (52W)-115.95%
Year-to-Date Return-64.77%
5-Day Price Return-11.84%
EPS Normalized (Annual)$-55.83
ROA (5Y Avg)-325.96%
Net Profit Margin (Annual)-7652.75%
Month-to-Date Return186.45%
Cash Flow / Share (TTM)$-4.09
EBITD / Share (Annual)$-33.65
Operating Margin (Annual)-6548.80%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-784.25%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-25.77
P/TBV (Quarterly)0.78x
P/B Ratio (Annual)3.92x
Dividend / Share (TTM)$0.00
Inventory Turnover (TTM)33.29x
Pretax Margin (TTM)-7718.38%
Book Value / Share (Annual)$7.64
Price vs S&P 500 (13W)31.19%
Dividend Yield (TTM)0.17%
Beta2.45x
P/FCF (Annual)7.04x
Revenue / Share (TTM)$0.00
ROE (TTM)-169.40%
52-Week Low$3.18
vGradeC
gGradeF
mGradeD
vgmGradeD
Show chart for
Analyst Recommendations
Dec 2022
Jan 2023
Feb 2023
Mar 2023
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ERNAErnexa Therapeutics Inc. Common Stock | C | F | D | $9.12 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Ernexa Therapeutics is a biotechnology company developing cell-engineered medicines for cancer and autoimmune diseases. The company's proprietary platform converts induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs) to create off-the-shelf cellular therapies, eliminating the need for patient-specific cell harvesting. This approach offers potential advantages in manufacturing scalability and cost-efficiency.